These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
218 related articles for article (PubMed ID: 36709149)
21. Advances in the development of chimeric antigen receptor-T-cell therapy in B-cell acute lymphoblastic leukemia. Zhang X; Li JJ; Lu PH Chin Med J (Engl); 2020 Feb; 133(4):474-482. PubMed ID: 31977556 [TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia. Gu R; Liu F; Zou D; Xu Y; Lu Y; Liu B; Liu W; Chen X; Liu K; Guo Y; Gong X; Lv R; Chen X; Zhou C; Zhong M; Wang H; Wei H; Mi Y; Qiu L; Lv L; Wang M; Wang Y; Zhu X; Wang J J Hematol Oncol; 2020 Sep; 13(1):122. PubMed ID: 32894185 [TBL] [Abstract][Full Text] [Related]
23. Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis. Anagnostou T; Riaz IB; Hashmi SK; Murad MH; Kenderian SS Lancet Haematol; 2020 Nov; 7(11):e816-e826. PubMed ID: 33091355 [TBL] [Abstract][Full Text] [Related]
24. UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial. Benjamin R; Jain N; Maus MV; Boissel N; Graham C; Jozwik A; Yallop D; Konopleva M; Frigault MJ; Teshima T; Kato K; Boucaud F; Balandraud S; Gianella-Borradori A; Binlich F; Marchiq I; Dupouy S; Almena-Carrasco M; Pannaux M; Fouliard S; Brissot E; Mohty M; Lancet Haematol; 2022 Nov; 9(11):e833-e843. PubMed ID: 36228643 [TBL] [Abstract][Full Text] [Related]
25. CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials. Leahy AB; Newman H; Li Y; Liu H; Myers R; DiNofia A; Dolan JG; Callahan C; Baniewicz D; Devine K; Wray L; Aplenc R; June CH; Grupp SA; Rheingold SR; Maude SL Lancet Haematol; 2021 Oct; 8(10):e711-e722. PubMed ID: 34560014 [TBL] [Abstract][Full Text] [Related]
26. CD19 CAR-T Cells With Membrane-Bound IL-15 for B-Cell Acute Lymphoblastic Leukemia After Failure of CD19 and CD22 CAR-T Cells: Case Report. Sun Y; Su Y; Wang Y; Liu N; Li Y; Chen J; Qiao Z; Niu J; Hu J; Zhang B; Ning H; Hu L Front Immunol; 2021; 12():728962. PubMed ID: 34691036 [TBL] [Abstract][Full Text] [Related]
27. Integrating CAR T-Cell Therapy and Transplantation: Comparisons of Safety and Long-Term Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation After CAR T-Cell or Chemotherapy-Based Complete Remission in B-Cell Acute Lymphoblastic Leukemia. Zhao YL; Liu DY; Sun RJ; Zhang JP; Zhou JR; Wei ZJ; Xiong M; Cao XY; Lu Y; Yang JF; Zhang X; Lu DP; Lu P Front Immunol; 2021; 12():605766. PubMed ID: 34025637 [TBL] [Abstract][Full Text] [Related]
28. Efficacy and Safety of Children With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia After Anti-CD19 CAR T-Cell Therapy Without Bridging Transplantation. Shang Q; Xue L; Lu A; Jia Y; Zuo Y; Zeng H; Zhang L Clin Lymphoma Myeloma Leuk; 2024 Jun; 24(6):392-399.e5. PubMed ID: 38429221 [TBL] [Abstract][Full Text] [Related]
29. Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies. Benjamin R; Graham C; Yallop D; Jozwik A; Mirci-Danicar OC; Lucchini G; Pinner D; Jain N; Kantarjian H; Boissel N; Maus MV; Frigault MJ; Baruchel A; Mohty M; Gianella-Borradori A; Binlich F; Balandraud S; Vitry F; Thomas E; Philippe A; Fouliard S; Dupouy S; Marchiq I; Almena-Carrasco M; Ferry N; Arnould S; Konto C; Veys P; Qasim W; Lancet; 2020 Dec; 396(10266):1885-1894. PubMed ID: 33308471 [TBL] [Abstract][Full Text] [Related]
30. [Long-term safety and activity of humanized CD19 chimeric antigen receptor T cells for children and young adults with relapsed/refractory acute lymphoblastic leukemia]. Wang SY; Zhao LN; Cheng H; Shi M; Chen W; Qi KM; Sun C; Wang X; Cao J; Xu KL Zhonghua Xue Ye Xue Za Zhi; 2022 Jul; 43(7):557-561. PubMed ID: 36709132 [No Abstract] [Full Text] [Related]
31. CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial. Cordoba S; Onuoha S; Thomas S; Pignataro DS; Hough R; Ghorashian S; Vora A; Bonney D; Veys P; Rao K; Lucchini G; Chiesa R; Chu J; Clark L; Fung MM; Smith K; Peticone C; Al-Hajj M; Baldan V; Ferrari M; Srivastava S; Jha R; Arce Vargas F; Duffy K; Day W; Virgo P; Wheeler L; Hancock J; Farzaneh F; Domning S; Zhang Y; Khokhar NZ; Peddareddigari VGR; Wynn R; Pule M; Amrolia PJ Nat Med; 2021 Oct; 27(10):1797-1805. PubMed ID: 34642489 [TBL] [Abstract][Full Text] [Related]
32. Systematic Review and Meta-analysis of CD19-Specific CAR-T Cell Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia in the Pediatric and Young Adult Population: Safety and Efficacy Outcomes. Aamir S; Anwar MY; Khalid F; Khan SI; Ali MA; Khattak ZE Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e334-e347. PubMed ID: 33573914 [TBL] [Abstract][Full Text] [Related]
33. Long-term follow-up of CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation. Chen YH; Zhang X; Cheng YF; Chen H; Mo XD; Yan CH; Chen Y; Han W; Sun YQ; Wang Y; Zhang XH; Xu LP; Liu KY; Yang J; Zhang J; Zhang GL; Shi Y; Su YC; Li WQ; Xu L; Song D; Zhang M; Lu P; Huang XJ Cytotherapy; 2020 Dec; 22(12):755-761. PubMed ID: 32861622 [TBL] [Abstract][Full Text] [Related]
34. Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia. Cai B; Guo M; Wang Y; Zhang Y; Yang J; Guo Y; Dai H; Yu C; Sun Q; Qiao J; Hu K; Zuo H; Dong Z; Zhang Z; Feng M; Li B; Sun Y; Liu T; Liu Z; Wang Y; Huang Y; Yao B; Han W; Ai H J Hematol Oncol; 2016 Nov; 9(1):131. PubMed ID: 27887660 [TBL] [Abstract][Full Text] [Related]
35. [Safety and efficacy of patients with refractory B-lymphoblastic leukemia treated with anti-CD19 CAR-T cell bridging to allogeneic hematopoietic stem cell transplantation]. Ai H; Yin QS; Wang Q; Fu YW; Wei XD; Song YP Zhonghua Xue Ye Xue Za Zhi; 2020 Mar; 41(3):239-244. PubMed ID: 32311895 [No Abstract] [Full Text] [Related]
36. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Shah BD; Ghobadi A; Oluwole OO; Logan AC; Boissel N; Cassaday RD; Leguay T; Bishop MR; Topp MS; Tzachanis D; O'Dwyer KM; Arellano ML; Lin Y; Baer MR; Schiller GJ; Park JH; Subklewe M; Abedi M; Minnema MC; Wierda WG; DeAngelo DJ; Stiff P; Jeyakumar D; Feng C; Dong J; Shen T; Milletti F; Rossi JM; Vezan R; Masouleh BK; Houot R Lancet; 2021 Aug; 398(10299):491-502. PubMed ID: 34097852 [TBL] [Abstract][Full Text] [Related]
37. Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation. Chen Y; Cheng Y; Suo P; Yan C; Wang Y; Chen Y; Han W; Xu L; Zhang X; Liu K; Chang L; Xiao L; Huang X Br J Haematol; 2017 Nov; 179(4):598-605. PubMed ID: 29076142 [TBL] [Abstract][Full Text] [Related]
38. Donor-derived CAR-T Cells Serve as a Reduced-intensity Conditioning Regimen for Haploidentical Stem Cell Transplantation in Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: Case Report and Review of the Literature. Zhang C; Kong PY; Li S; Chen T; Ni X; Li Y; Wang M; Liu Y; Gao L; Gao L; Peng XG; Sun AH; Wang P; Yang Z; Zhang X; Qian C J Immunother; 2018; 41(6):306-311. PubMed ID: 29864079 [TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of CD19 CAR-T cell therapy for patients with B cell acute lymphoblastic leukemia involving extramedullary relapse. Huang L; Zhang M; Wei G; Zhao H; Hu Y; Huang H Zhejiang Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 51(2):151-159. PubMed ID: 36161297 [TBL] [Abstract][Full Text] [Related]
40. Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study. Yang J; He J; Zhang X; Li J; Wang Z; Zhang Y; Qiu L; Wu Q; Sun Z; Ye X; Yin W; Cao W; Shen L; Sersch M; Lu P Blood Cancer J; 2022 Jul; 12(7):104. PubMed ID: 35798714 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]